Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (Weighted Average) (2016 - 2025)

Ani Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $20.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.8% year-over-year to $20.1 million; the TTM value through Dec 2025 reached $20.1 million, up 3.8%, while the annual FY2025 figure was $20.1 million, 3.8% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $20.1 million at Ani Pharmaceuticals, up from $19.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $20.1 million in Q4 2025 and bottomed at $12.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $17.4 million (2023), against an average of $16.9 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) rose 0.65% in 2021 before it surged 35.09% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $12.6 million in 2021, then rose by 29.09% to $16.3 million in 2022, then increased by 10.71% to $18.0 million in 2023, then grew by 7.32% to $19.3 million in 2024, then grew by 3.8% to $20.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Shares Outstanding (Weighted Average) are $20.1 million (Q4 2025), $19.8 million (Q3 2025), and $19.8 million (Q2 2025).